Pharmacovigilance is concerned with the detection, assessment, understanding, and prevention of adverse reactions to medicines. It is helpful to prevent undesired harm sustained by the patient due to inappropriate or unsafe use of medicinal agents. As the use of drugs and polypharmacy increase in prevalence, pharmacovigilance gains relevance and momentum. Practice-based research networks have the potential to enhance health research by promoting earlier detection of adverse events at a decreased level of cost. This article explores the recent evidence of an improved benefit of administering non-steroidal antiinflammatory drugs (NSAIDs) in the fasting state, and authors propose that an improved pharmacovigilance system is both needed and feasible provided records are adapted to a nationwide integration of pharmacoepidemiology data.
operative learning system inside an institution than implementing someone else's lessons [3] . Therefore, the focus on quality care requires promoting research, as current standards of care are far from optimal. One example of this comes from a recent systematic review comparing oral analgesics in fed and fasting states [4] . The fed state reduced maximum plasma concentration of acetylsalicylic acid, ibuprofen, diclofenac, and acetaminophen (paracetamol) from 15 to 56 % of the corresponding fasting maximum concentration. Accordingly, time to maximum plasma concentration was also increased in the fed state (from 1.30 to 2.80 times longer than in the fasting state) for those same analgesic drugs. These pharmacokinetic differences are expected to impact therapeutic efficacy. If high-quality large-scale evidence were available on the efficiency of analgesic drugs for patients taking them in different conditions (namely fasted and fed states), this could have been suspected and investigated earlier. with drug Y or patient C reported certain side effects with drug Z, all these individual pieces of information should be compiled into some common database of medical records where these variables can be collectively appreciated.
Furthermore, a tool to estimate the probability of an adverse drug reaction like the ten-item algorithm from Naranjo et al. [7] should also be incorporated. Such a data repository can derive from practice-based research networks, which can indeed provide invaluable pharmacoepidemiological information [2, 8] .
In order to comply with principles of good clinical practice, such data repository must not include individual pieces of information that could identify patients (e.g., name, detailed address, identification card number, etc.).
Only variables of medical interest, including those that may be of help in spotting protective or risk features for treatment response or complications, are warranted. The development of such record at a nationwide level would compete with large-scale observational studies at incredibly lower costs.
The infrastructure of practice-based research networks would also be advantageous to both patients and pharmaceutical companies as it would accelerate the detection of safety issues unidentified at earlier stages of development as well as anticipate assessment of efficacy in a relatively controlled environment.
This central data repository should not receive inputs only from health professionals. Electronic health records (EHR) are an opportunity to put into practice a proactive approach to medical information collection, not only reminding doctors to assess the effects of prescriptions at a later appointment but also by acquiring data directly at the patient level, promoting empowerment and responsibility among patients and carers [9] .
This would truly be a person-centric approach to health care and research [2] .
Practice-based research networks can bring further advantage by promoting detection and reporting of medical errors. Medical incidents and adverse events in primary care/general practice are erroneously at a very low level [10] . This is probably a consequence of both ineffective reporting mechanisms and fragmented levels of information. Without a major focus on quality assessment and safety incidents reporting, the opportunity to improve practices will be postponed until key messages are made clear by other sources of evidence. The amount of time we are willing to wait for these feedback mechanisms to be fully operational depends entirely on us, health care professionals. Indeed, a considerable amount of effort has been dedicated to patient safety for decades now. However, we believe that further individual adherence to incident reporting will only be achieved with promotion of an effective nationwide EHR. We should urge national and international health authorities to put forward legal requirements on feedback mechanisms of medical practice.
Despite Critical Path to New Medical Products, which raised concerns and proposed solutions for the growing crisis in moving basic discoveries to the market [11] . This document was followed by the Critical Path Opportunities List, which identified specific activities that could improve the accuracy of tests that predict the safety and efficacy of potential medical products [12] .
Such initiatives and supporting technologies are making it possible to implement cutting-edge information systems critical to fostering public health safety. An example of this is the Mini-Sentinel safety pilot program, the pioneer project towards a nationwide rapid-response electronic safety surveillance system for drugs and other medical products [13] . As of the first trimester of 2014, it already included over 30 collaborating healthcare institutions, nearly 100 million patients, 2.4 billion medical encounters, and 2.9 billion prescription drug dispensings [14] . An endeavor of such magnitude will be retrieving precious information from everyday clinical data that will complement existing systems already in place to track reports of adverse events linked to the use of regulated products.
However, stakeholders ought not to be shortsighted and it is imperative that long-run projects are devised. Nationwide electronic health records and updated metrics for health outcomes must be put in place so that practitioners are captivated to use them. 
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